Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes CE (2015) Tumor oncogene (KRAS) status and risk of venous Thrombosis in patients with metastatic Colorectal cancer. J Thromb Haemost 13(6):998–1003

Article  CAS  PubMed  Google Scholar 

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu MJ, Chen L, Chen R, Liu YX, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M (2016) Horbinski C.: Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica 132(6):917–930

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant’Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M (2014) Grp Assoc Italiana Ric Canc: clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124(7):1062–1069

Article  CAS  Google Scholar 

Dou F, Zhang Y, Yi J, Zhu M, Zhang S, Zhang D, Zhang Y (2020) Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell Lung cancer: a prospective cohort study. Thromb Res 186:36–41

Article  CAS  Google Scholar 

Su YP, Huo MR, Hua L, Zhang Y, Yi JW, Zhang S, Li J, Zhang YH (2021) Association of Venous Thromboembolism and early mortality in patients with newly diagnosed metastatic non-small cell Lung Cancer. Cancer Manage Res 13:4031–4040

Article  CAS  Google Scholar 

Al-Samkari H, Leiva O, Dagogo-Jack I, Shaw A, Lennerz J, Iafrate AJ, Bendapudi PK, Connors JM (2020) Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J Thorac Oncol 15(9):1497–1506

Article  CAS  Google Scholar 

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell Lung cancer. Nature 448(7153):561–U563

Article  CAS  PubMed  Google Scholar 

Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell Lung cancer. Cancer Res 68(13):4971–4976

Article  CAS  PubMed  Google Scholar 

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic Lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11–23. https://doi.org/10.1038/nrc2291

Article  CAS  Google Scholar 

Zhang SS, Nagasaka M, Zhu VW, Ou SI (2021) Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer 158:126–136. https://doi.org/10.1016/j.lungcan.2021.06.012

Article  CAS  Google Scholar 

Atherly AJ, Camidge DR (2012) The cost-effectiveness of screening Lung cancer patients for targeted drug sensitivity markers. Br J Cancer 106:1100–1106. https://doi.org/10.1038/bjc.2012.60

Article  CAS  PubMed Central  PubMed  Google Scholar 

Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61:163–169. https://doi.org/10.1016/j.lungcan.2007.12.013

Article  PubMed  Google Scholar 

Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, Sugiyama Y, Mano H (2008) A mouse model for EML4-ALK-positive Lung cancer. Proc Natl Acad Sci USA 105(50):19893–19897

Article  CAS  PubMed Central  PubMed  Google Scholar 

Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in Lung cancer. Clin Cancer Res 14:4275–4283. https://doi.org/10.1158/1078-0432.CCR-08-0168

Article  CAS  PubMed Central  Google Scholar 

Hallberg B, Palmer RH (2013) Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology (vol 13, pg 685, 2012). Nat Rev Cancer 13(11):821–821

Article  Google Scholar 

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Mino-Kenudson GL, Wei M, Shreeve GC, Ratain SM, Settleman MJ, Christensen J, Haber JG, Wilner DA, Salgia K, Shapiro R, Clark GI (2010) J. W., Iafrate A. J.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703

Le T, Gerber DE (2017) ALK alterations and inhibition in Lung cancer. Semin Cancer Biol 42:81–88. https://doi.org/10.1016/j.semcancer.2016.08.007

Article  CAS  PubMed  Google Scholar 

Golding B, Luu A, Jones R, Viloria-Petit AM (2018) The function and therapeutic targeting of anaplastic Lymphoma kinase (ALK) in non-small cell Lung cancer (NSCLC). Mol Cancer 17:52. https://doi.org/10.1186/s12943-018-0810-4

Article  CAS  PubMed Central  PubMed  Google Scholar 

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic Lymphoma kinase and c-Met, in experimental models of anaplastic large-cell Lymphoma. Mol Cancer Ther 6:3314–3322. https://doi.org/10.1158/1535-7163.MCT-07-0365

Article  CAS  PubMed  Google Scholar 

Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. (1986) Recombinant Tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 83(12):4533–4537

Article  CAS  PubMed Central  PubMed  Google Scholar 

Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172(6):1535–1545

Article  CAS  PubMed  Google Scholar 

Abdol Razak N, Elaskalani O, Metharom P (2017) : Pancreatic Cancer-Induced Neutrophil Extracellular traps: a potential contributor to Cancer-Associated Thrombosis. Int J Mol Sci 18(3)

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P (2018) : Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers 10(10)

Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ (2005) PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 65(4):1406–1413

Article  CAS  PubMed  Google Scholar 

Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB (2007) Tissue factor expression, angiogenesis, and Thrombosis in Pancreatic cancer. Clin Cancer Res 13(10):2870–2875

Article  CAS  Google Scholar 

Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C (2009) Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 206(9):1913–1927

Article  CAS  PubMed Central  PubMed  Google Scholar 

Riedl J, Preusser M, Nazari PMS, Posch F, Panzer S, Marosi C, Birner P, Thaler J, Brostjan C, Lotsch D, Berger W, Hainfellner JA, Pabinger I, Ay C (2017) Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 129(13):1831–1839

Article  CAS  PubMed  Google Scholar 

Belghasem M, Roth D, Richards S, Napolene MA, Walker J, Yin WQ, Arinze N, Lyle C, Spencer C, Francis JM, Thompson C, Andry C, Whelan SA, Lee N, Ravid K (2019) Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis. Blood 134(26):2399–2413

Article  PubMed Central  Google Scholar 

Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, Wagner DD (2015) Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein Thrombosis in mice. J Thromb Haemost 13:1310–1319. https://doi.org/10.1111/jth.13002

Article  CAS  PubMed Central  PubMed  Google Scholar 

Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT (2014) Two novel ALK mutations mediate Acquired Resistance to the next-generation ALK inhibitor Alectinib. Clin Cancer Res 20(22):5686–5696

Article  CAS  PubMed Central  PubMed  Google Scholar 

Campello E, Ilich A, Simioni P, Key NS (2019) The relationship between Pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. Br J Cancer 121(5):359–371

Article  PubMed Central  PubMed  Google Scholar 

Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY (2022) : Cancer-associated venous thromboembolism. Nat Reviews Disease Primers 8(1)

Hisada Y, Mackman N (2019) Tissue factor and Cancer: regulation, Tumor Growth, and Metastasis. Semin Thromb Hemost 45(4):385–395

Article  CAS  PubMed Central  PubMed  Google Scholar 

Felts SJ, Stoflet ES, Eggers CT, Getz MJ (1995) Tissue factor gene transcription in serum-stimulated fibroblasts is mediated by recruitment of c-Fos into specific AP-1 DNA-binding complexes. Biochemistry 34(38):12355–12362

Article  CAS  PubMed  Google Scholar 

Syrovets T, Jendrach M, Rohwedder A, Schüle A, Simmet T (2001) Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood 97(12):3941–3950

Article  CAS  PubMed  Google Scholar 

Liu Y, Pelekanakis K, Woolkalis MJ (2004) Thrombin and Tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun. J Biol Chem 279(34):36142–36147

Article  CAS  PubMed  Google Scholar 

AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human) [